After-market Movers For July 25 (AMZN, SBUX, GILD, EXPE, ZNGA, SWI, TPX, VRTX)

(RTTNews) - Gainers:

Starbucks Corp. (SBUX) gained over 6 percent to $72.55. The company's third quarter profit and net revenues increased from the prior year period and were above Wall Street view. The company also raised its full year fiscal 2013 earnings per share forecast.

Gilead Sciences Inc. (GILD) rose 5 percent to $64.26. The company's second quarter earnings improved from the year-ago quarter and its adjusted earnings per share matched analysts' estimate. Total revenues for the quarter increased 15 percent and came above Street view.

Decliners:

Amazon.com Inc. (AMZN) declined 2 percent to $297.05 after reporting a surprise loss in its second quarter. Sales for the quarter increased 22 percent, but marginally missed the consensus estimate. The company expects to report an operating loss in its third quarter and sales in-line with Street view.

Expedia Inc. (EXPE) plunged 23 percent to $49.55. The company's second quarter earnings declined sharply from the prior year period and its adjusted earnings per share missed analysts' estimate. Revenue for the quarter improved 16 percent, but came below the consensus estimate.

Zynga, Inc. (ZNGA) fell 13 percent to $3.03. The company's second quarter net loss narrowed from the year-ago quarter and its adjusted loss per share were lesser than what analysts' had estimated. Revenue for the quarter declined, but managed to come above Street view. Meanwhile, the company forecast third quarter loss larger than Street view and revenue in-line with analysts' estimate. Zynga also announced that it has decided not to pursue a license for real money gaming in the U.S.

SolarWinds, Inc. (SWI) plummeted 21 percent to $36.40. The company's second quarter profit was higher than the year-ago quarter and adjusted earnings per share topped Street view. Revenues increased 21 percent, but missed the consensus estimate. The company forecast third quarter results below analysts' expectations. The company also lowered its fiscal year 2013 guidance.

Tempur Sealy International Inc. (TPX) fell 10 percent to $37.50. The company slipped to a loss in its second quarter. Net sales doubled from the year-ago quarter, but missed the consensus estimate. The company also lowered its financial outlook for the full year stating that the steps it took to return Tempur North America to growth are taking longer than expected.

Vertex Pharmaceuticals Inc. (VRTX) declined 8 percent to $80.00. The U.S. Food and Drug Administration has placed a partial clinical hold on the company's ongoing Phase 2 U.S. study of the nucleotide analogue hepatitis C virus polymerase inhibitor VX-135.